Retrophin Inc (NASDAQ:RTRX) was the recipient of unusually large options trading on Wednesday. Stock investors acquired 3,982 put options on the company. This represents an increase of 1,702% compared to the typical daily volume of 221 put options.
Shares of NASDAQ:RTRX opened at $17.94 on Thursday. The firm has a market cap of $778.19 million, a price-to-earnings ratio of -7.06 and a beta of 0.91. Retrophin has a 12-month low of $17.85 and a 12-month high of $33.00. The company has a debt-to-equity ratio of 0.61, a current ratio of 4.74 and a quick ratio of 4.68.
Retrophin (NASDAQ:RTRX) last announced its quarterly earnings data on Tuesday, May 7th. The biopharmaceutical company reported ($0.99) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.58) by ($0.41). The company had revenue of $39.57 million for the quarter, compared to analysts’ expectations of $41.40 million. Retrophin had a negative net margin of 62.51% and a negative return on equity of 33.53%. The firm’s quarterly revenue was up 3.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.14) EPS. As a group, research analysts anticipate that Retrophin will post -2.47 EPS for the current year.
A number of research analysts have recently commented on the company. BidaskClub upgraded Retrophin from a “sell” rating to a “hold” rating in a research note on Thursday, March 14th. William Blair restated an “outperform” rating on shares of Retrophin in a research note on Wednesday, April 17th. TheStreet cut Retrophin from a “c-” rating to a “d+” rating in a research note on Friday, February 22nd. Zacks Investment Research upgraded Retrophin from a “strong sell” rating to a “hold” rating in a research note on Wednesday, February 27th. Finally, ValuEngine cut Retrophin from a “strong-buy” rating to a “buy” rating in a research note on Thursday, January 17th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and six have given a buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $45.67.
In other news, SVP William E. Rote sold 1,250 shares of Retrophin stock in a transaction that occurred on Friday, February 15th. The stock was sold at an average price of $21.44, for a total value of $26,800.00. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, CEO Steve Aselage sold 2,130 shares of Retrophin stock in a transaction that occurred on Tuesday, February 12th. The stock was sold at an average price of $21.44, for a total value of $45,667.20. Following the completion of the sale, the chief executive officer now owns 258,707 shares in the company, valued at $5,546,678.08. The disclosure for this sale can be found here. Over the last quarter, insiders sold 12,917 shares of company stock worth $277,140. Corporate insiders own 4.32% of the company’s stock.
Several institutional investors have recently bought and sold shares of RTRX. Man Group plc increased its holdings in shares of Retrophin by 19.0% in the 3rd quarter. Man Group plc now owns 71,742 shares of the biopharmaceutical company’s stock worth $2,061,000 after purchasing an additional 11,455 shares in the last quarter. MetLife Investment Advisors LLC increased its holdings in shares of Retrophin by 55.7% in the 3rd quarter. MetLife Investment Advisors LLC now owns 29,333 shares of the biopharmaceutical company’s stock worth $843,000 after purchasing an additional 10,491 shares in the last quarter. AQR Capital Management LLC grew its holdings in shares of Retrophin by 117.5% in the third quarter. AQR Capital Management LLC now owns 29,132 shares of the biopharmaceutical company’s stock worth $837,000 after acquiring an additional 15,740 shares during the period. Legal & General Group Plc grew its holdings in shares of Retrophin by 33.5% in the third quarter. Legal & General Group Plc now owns 13,541 shares of the biopharmaceutical company’s stock worth $389,000 after acquiring an additional 3,395 shares during the period. Finally, Vanguard Group Inc. grew its holdings in shares of Retrophin by 1.4% in the third quarter. Vanguard Group Inc. now owns 1,928,602 shares of the biopharmaceutical company’s stock worth $55,409,000 after acquiring an additional 26,016 shares during the period.
ILLEGAL ACTIVITY NOTICE: “Investors Purchase High Volume of Retrophin Put Options (RTRX)” was first posted by American Banking News and is the sole property of of American Banking News. If you are reading this story on another site, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be read at https://www.americanbankingnews.com/2019/05/09/investors-purchase-high-volume-of-retrophin-put-options-rtrx.html.
Retrophin Company Profile
Retrophin, Inc, a biopharmaceutical company, focuses on the identification, development, acquisition, and commercialization of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola, a tiopronin tablet for the treatment of cystinuria.
Featured Article: Terms to Better Understand Call Options
Receive News & Ratings for Retrophin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin and related companies with MarketBeat.com's FREE daily email newsletter.